CCM
CLVS

Copernicus Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Copernicus Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-141,345
Closed -$6.43M – 22
2018
Q2 		$6.43M Buy
141,345
+70,253
+99% +$3.42M 4.66% 10
2018
Q1 		$3.75M Buy
71,092
+34,548
+95% +$2.02M 2.99% 16
2017
Q4 		$2.48M Buy
+36,544
New +$2.56M 1.85% 22

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Copernicus Capital Management's CLVS Position: Q3 2018 in Review

Copernicus Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 141,345 shares — an estimated $6.43M sold.

Copernicus Capital Management first reported a position in CLVS in Q4 2017 and held it in 3 quarters. The position peaked at $6.43M in Q2 2018. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Copernicus Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Copernicus Capital Management sold 141,345 Clovis Oncology, Inc. shares in Q3 2018, an estimated $6.43M.
  • Copernicus Capital Management first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 3 quarters.
  • Copernicus Capital Management's Clovis Oncology, Inc. position peaked at $6.43M in Q2 2018.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Copernicus Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.